Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Trial details
- Registry ID
- NCT05954143
- Drugs studied
- BDC-1001, Pertuzumab
TrialRedline tracks 1 clinical trial sponsored by Bolt Biotherapeutics, Inc.: 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerNCT05954143 | BDC-1001, Pertuzumab | Terminated | 2024-09-20Actual |
Names as written in the registry records.